Growth & GHPeptideEvidence CNo primary references

PEG-MGF

PEGylated Mechano Growth Factor

aka PEGylated MGF · PEG-MGF · pegylated mechano growth factor

A PEGylated IGF-1 splice variant researched for systemic satellite cell activation and extended muscle repair signalling.

Half-life

1 day

estimated

Tmax

4 h

Sequence

Read this before quoting the sequence

PEG-MGF is described in vendor material as the MGF E-domain peptide (see the 'mgf' entry) conjugated to polyethylene glycol. No peer-reviewed publication describing a defined PEG-MGF conjugate - its peptide sequence, PEG molecular weight, attachment chemistry or degree of PEGylation - was located, so no sequence can be stated. Without a specified PEG size and linkage, PEG-MGF is not a defined chemical entity.

Mechanism of action

PEG-MGF is a PEGylated form of Mechano Growth Factor, which is a splice variant of IGF-1. It works by activating satellite cells in muscle tissue, promoting muscle repair and growth. The PEGylation extends its half-life, allowing for systemic distribution and prolonged activity compared to the non-PEGylated form.

What the evidence actually shows

Grade C

There are no human clinical trials specifically evaluating PEG-MGF. Most evidence comes from animal studies and in vitro experiments showing enhanced muscle repair and growth. Human data is lacking, and more research is needed to confirm efficacy and safety in humans.

Regulatory status

Status

Not approved anywhere. Not a defined pharmaceutical entity.

Clinical stage

None. A Europe PMC title search for 'PEG-MGF' returned zero results, and a broader search for 'pegylated mechano growth factor' returned no paper describing such a conjugate. There is no preclinical or clinical literature.

WADA

The WADA Prohibited List section S2.3 prohibits 'Mechano growth factors (MGFs)' at all times. A PEGylated MGF is an MGF preparation and would fall within that class.

research_compound

PEG-MGF is not approved for medical use in the UK and is considered a research compound by the MHRA.

Source ↗

Pharmacokinetics

Half-life

1 day

Tmax

4 h

Absorption

subcutaneous

Elimination

renal

Washout

7 days

Low-confidence pharmacokinetics

These figures are recorded as estimated rather than measured in a published PK study. Treat them as an order of magnitude. Anything downstream of them — accumulation, steady state, washout — inherits that uncertainty.

Dosing — what backs each figure

PEG-MGF (PEGylated mechano growth factor) has no human trial data and no published animal dosing regimen distinct from unmodified MGF. Reviews of performance-enhancing peptides place it in the lowest evidence tier, alongside IGF-1 LR3 and AOD9604, where product composition and dose in the unregulated supply chain are themselves uncertain. Every circulating number - the microgram dose, the 2-3x weekly schedule and the 4-6 week cycle - originates from self-administration protocols.

Commonly circulatedNot established by any study

Dose: 100-200 mcg/dose
Frequency: 2-3x weekly
Cycle: 4-6 weeks· unsourced

Why this isn't evidence
PEG-MGF has no regulatory approval and no published clinical or systematic preclinical dosing; a 2026 review classifies it explicitly as an unregulated 'research compound' whose dose, frequency and stacking figures come from online self-administration protocols rather than evidence.

This figure is shown because it is what circulates and what people search for — not because it is supported. Cycle lengths in particular tend to be convention copied between compounds rather than anything derived from a compound's own pharmacokinetics.

No established human dose

No approved label or completed human trial establishes a dosing regimen for this compound. Anything presented as a standard protocol for it — anywhere — is someone's convention rather than a finding.

Handling and storage

No compound-specific stability data exists

No data of any kind was located. General peptide handling still applies — reconstitute gently, keep it cold, keep it dark — but any specific figure you see quoted for this compound elsewhere is someone's assumption, not a measurement.

→ Reconstitution walkthrough → Reconstitution calculator

Safety

Commonly reported

·Injection site irritation
·Transient hypoglycemia

Rarely reported

·Potential for abnormal tissue growth

Contraindications

·Active cancer
·Pregnancy

Drug interactions

·Insulin-like growth factor inhibitors, which may reduce its effectiveness

Reported combinations

Reported as synergistic

·IGF-1
·Creatine

Reported as antagonistic

·Corticosteroids, which may counteract muscle growth effects

Combination claims in this dataset are largely unsourced and should be treated as folk knowledge until a citation appears beside them.

References (0)

No verifiable primary references

We could not find a single citation for this compound carrying a PMID or DOI that resolves. That is itself the most useful thing this page can tell you: claims made about it elsewhere are not resting on indexed literature.

Data provenance

Chemistry and citations on this page were checked against primary sources on 2026-08-14. Values that could not be verified were left blank rather than filled with a plausible guess.

Could not verify
sequence, molecularFormula, molecularWeight, casNumber, pubchemCid, storage.lyophilized, storage.reconstituted, storage.lightSensitive, reconstitution.solvent, references

Research use only

This profile is educational reference material. It is not medical advice, not a prescription, and not an endorsement of self-administration. Compounds discussed here are research chemicals and most are not approved for human therapeutic use.

Related in Growth & GH

CJC-1295 (No DAC)

A modified GHRH analog with a short half-life. Commonly paired with a GHRP in research protocols to study pulsatile GH release.

CJC-1295 (with DAC)

A long-acting GHRH analogue research describes as sustaining elevated GH levels for up to eight days per dose.

Follistatin 344

A glycoprotein that binds and neutralises myostatin, the protein that naturally limits muscle growth.